Skip to main content
UTHR logo

United Therapeutics Corporation (UTHR) Stock: Price, Forecast & Analyst Target

United Therapeutics Corporation (UTHR) — MoonshotScore 97/100 (Exceptional band), calculated Nov 18, 2026. Price $577.34 (-1.16%), as of the Nov 18, 2026 trading session; market cap $24.6B.

Educational signal · not a buy or sell recommendation · How to read this

$577.34 −$6.76 (-1.16%) Market Cap $24.6B

United Therapeutics Corporation · UTHR · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-12: United Therapeutics is a profitable commercial drugmaker centered on pulmonary hypertension therapies, with Tyvaso contributing far more revenue than any other product. Tyvaso’s ability to extend into broader lung disease indications while preserving cash generation will determine whether the recent revenue plateau is temporary or a harder limit.

Price as of Nov 18, 2026

Key Statistics

97 of 100

MoonshotScore v2 · United Therapeutics (UTHR)

Exceptional
Business Quality Elite (95)
Financial Safety Fortress (99)
Valuation Full (49)
Growth Durability Growing (79)
Momentum Surging (85)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a fortress balance sheet and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Growing; Momentum: Surging.

  • EPS beat 4 of the last 8 reports
  • Altman Z 22.92 · Piotroski F 7
  • ROE 19.1% · ROA 10.9% · current ratio 4.61

Helping: business quality, balance-sheet strength, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for UTHR (57 recorded, newest six shown)
RecordedScoreBand
97Exceptional
97Exceptional
97Exceptional
97Exceptional
97Exceptional
97Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$577.34
Change on the day-1.16%
52-week range$455.63–$614.23
Market capitalisation$24.6B—
Price / earnings (trailing)20.45
Shares traded on the day416.6K
Beta (volatility vs the S&P 500)0.56

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $419, high $599, latest $577. $599 $419 high $599 Oct 17, 2025 Nov 18, 2026 · $577 $433Oct 17, 2025$445Oct 31, 2025$466Nov 14, 2025$486Nov 28, 2025$494Dec 12, 2025$507Dec 26, 2025$483Jan 9, 2026$469Jan 23, 2026$485Feb 6, 2026$473Feb 20, 2026$478Mar 6, 2026$524Mar 20, 2026$565Apr 2, 2026$588Apr 17, 2026$570May 1, 2026$569May 15, 2026$557May 29, 2026$546Jun 12, 2026$543Jun 26, 2026$547Jul 10, 2026$528Jul 24, 2026$539Aug 7, 2026$513Aug 21, 2026$488Sep 4, 2026$495Sep 18, 2026$542Oct 2, 2026$533Oct 16, 2026$599Oct 30, 2026$591Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for United Therapeutics (UTHR): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Strong
Valuation Neutral
Growth Durability Moderate
Momentum Strong

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Strong
Revenue Growth Moderate
ROE Moderate
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is United Therapeutics (UTHR), and what does it report?

Short answer · as of

United Therapeutics is already a scaled commercial drug business, not a development-stage biotechnology company awaiting an inaugural product. It sells inhaled, infused and oral therapies for pulmonary vascular disease, alongside Unituxin for high-risk neuroblastoma.

Reported revenue largely measures sales of named medicines rather than licensing milestones or research partnerships. Tyvaso dominates the product mix, while Remodulin, Orenitram, Unituxin and Adcirca provide smaller revenue streams; this concentration makes patient adoption and indication expansion within the Tyvaso franchise especially consequential.

2 · Latest results

What do the latest results show for United Therapeutics (UTHR)?

Revenue edged above the immediately preceding period but remained below the earlier run rate and missed the external estimate. Gross profit, operating profit, net income and diluted earnings rebounded sequentially, while research spending rose and selling and administrative expense declined.

The visible operating mechanism was improved gross profit combined with lower selling and administrative expense, which more than absorbed higher research spending. Management says underlying fundamentals remain strong and expects improved performance later in the year, but the reported revenue series has yet to show that acceleration.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$800M$339M$7.16 (diluted)
Q4 FY2025$790M$364M$7.70 (diluted)
Q1 FY2026$782M$275M$5.82 (diluted)
Q2 FY2026$783M$333M$7.27 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for United Therapeutics (UTHR)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

United Therapeutics carries no debt, holds cash and investments well above total liabilities, and has produced positive operating cash flow throughout the displayed quarterly series. High gross and operating margins give the company unusual capacity to fund research and capital spending internally.

Cash and short-term investments declined across the broader reported window before recovering sharply in the latest periods; long-term investments add another layer to the reserve. Capital spending remains substantial and operating cash flow can vary meaningfully between periods, so the direction of free cash generation matters more than any isolated quarter.

Tyvaso concentration is the sharper business risk. A demand setback, launch delay or regulatory constraint affecting that franchise would strike the product that funds much of the company’s research agenda, while the remaining medicines are not yet large enough to replace it readily.

4 · What to check next?

What should you watch next at United Therapeutics (UTHR)?

Short answer · as of

Current published price targets run low $368.00 · high $850.00 · consensus $671.73 · median $703.00 against a quoted price of $577.34 (as of Nov 18, 2026).

Revenue breaking above its recent plateau without sacrificing earnings resilience would provide the clearest near-term evidence of renewed momentum. The pending consensus expects revenue near the recent run rate and earnings below the latest result, while recent history shows revenue expectations have been harder to clear consistently than earnings expectations.

Tyvaso-specific evidence deserves greater weight than consolidated guidance: launch trajectory, uptake in broader lung disease, and the regulatory path for DPI and SMI formulations. Management says an IPF launch would begin with nebulized Tyvaso and that further FDA engagement is required for the other delivery formats.

Longer-range consensus assumes accelerating revenue and earnings, but the spread between revenue estimates widens materially farther out. Operating cash flow, capital spending and the durability of the recent cash recovery offer practical checks on whether commercial expansion is translating into additional financial capacity.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does United Therapeutics compare with its peers?

Short answer

United Therapeutics's score ranks 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

United Therapeutics has the margins, recurring profit, cash generation and debt-free balance sheet associated with a mature specialty pharmaceutical company. Its product concentration, however, remains closer to a focused biotechnology business: Tyvaso carries far more economic weight than the rest of the portfolio.

That combination changes the comparison. United Therapeutics is not chiefly dependent on outside financing to reach its next clinical or regulatory milestone, yet its growth profile still depends heavily on expanding a particular pulmonary franchise across indications and delivery formats.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Same industry, near in market value$68.29 Nov 18, 2026$16.7B98 5-pillar Nov 18, 2026
United Therapeutics (UTHR) — this page$577.34$24.6B97
Ascendis Pharma A/S (ASND) Same industry, near in market value$270.33 Nov 18, 2026$17.7B96 5-pillar Nov 18, 2026
argenx SE (ARGX) Same industry, near in market value$941.25 Nov 18, 2026$59.2B96 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$315.34 Nov 18, 2026$9.34B96 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$95.80 Nov 18, 2026$10.9B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.75 Nov 18, 2026$11.4B92 5-pillar Nov 18, 2026
Incyte Corporation (INCY) Named competitor$117.80 Nov 18, 2026$24.0B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$66.12 Nov 18, 2026$9.99B90 5-pillar Nov 18, 2026
Illumina, Inc. (ILMN) Named competitor$210.01 Nov 18, 2026$31.8B84 5-pillar Nov 18, 2026
Quest Diagnostics Incorporated (DGX) Named competitor$259.52 Nov 18, 2026$28.6B74 5-pillar Nov 18, 2026
Royalty Pharma plc (RPRX) Named competitor$68.67 Nov 18, 2026$39.5B73 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$368.00 – $850.00
Consensus target
$671.73
Median target
$703.00

Consensus record · Captured .

Measured against a quoted price of $577.34 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 13, 2026

Transactions
60
Identified insiders
1
Purchases
0
Sales
52
Other transactions
8

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held UTHR in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.30%$67.95MAdded +12.6% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about United Therapeutics (UTHR)?

Read these with our analysis →

What Investors Ask About United Therapeutics (UTHR) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

Why does Tyvaso matter so much to United Therapeutics?

Tyvaso generates far more revenue than any other medicine in the portfolio and anchors the company’s pulmonary franchise. Its adoption across approved uses and potential expansion into additional lung disease indications therefore have an outsized effect on companywide growth.

How will nebulized Tyvaso differ from Tyvaso DPI in the IPF launch?

Management says the IPF launch would begin with nebulized Tyvaso. DPI and SMI would require further FDA engagement before those delivery formats could join that indication.

What roles do Remodulin and Orenitram play beside Tyvaso?

Remodulin delivers treprostinil by infusion, while Orenitram provides an oral formulation for pulmonary arterial hypertension. They broaden delivery choice within the pulmonary franchise and contribute meaningful revenue, though neither approaches Tyvaso’s scale.

Why is Unituxin different from United Therapeutics’ pulmonary medicines?

Unituxin is a monoclonal antibody used for high-risk neuroblastoma, making it the commercial portfolio’s oncology outlier. It diversifies disease exposure, but its revenue contribution remains far below Tyvaso’s.

What is the UTHR stock price today?

The last price recorded for United Therapeutics Corporation (UTHR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the UTHR price target?

The analyst consensus price target for United Therapeutics Corporation (UTHR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • 1. What is United Therapeutics (UTHR), and what does it report?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Trailing twelve-month ratio set
  • 2. What do the latest results show for United Therapeutics (UTHR)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Annual revenue and net result (USD millions); Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for United Therapeutics (UTHR)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Revenue by segment; Annual revenue and net result (USD millions)
  • 4. What should you watch next at United Therapeutics (UTHR)?: Next earnings report; Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Management outlook — dated call excerpts; Analyst revenue and earnings estimates (average); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions)
  • 5. How does United Therapeutics compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions); Cash, investments and debt
  • FAQ: Why does Tyvaso matter so much to United Therapeutics?: Revenue by segment; Business description; Management outlook — dated call excerpts
  • FAQ: How will nebulized Tyvaso differ from Tyvaso DPI in the IPF launch?: Management outlook — dated call excerpts; Business description
  • FAQ: What roles do Remodulin and Orenitram play beside Tyvaso?: Business description; Revenue by segment
  • FAQ: Why is Unituxin different from United Therapeutics’ pulmonary medicines?: Business description; Revenue by segment
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold UTHR

Funds in our ETF coverage that list UTHR among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
Invesco S&P MidCap Quality ETF (XMHQ)3.48%
JPMorgan Small & Mid Cap Enhanced Equity ETF (JMEE)0.68%